Rigel Pharmaceuticals (RIGL) Total Debt (2019 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Total Debt of $44.9 million for Q1 2026, down 24.92% year-over-year from $59.7 million in Q1 2025, and down 45.37% quarter-over-quarter from $82.1 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Total Debt (2019 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Total Debt history runs 8 years deep, the most recent figure standing at $44.9 million for Q1 2026.
- In Q1 2026, Total Debt fell 24.92% year-over-year to $44.9 million; the TTM figure through Mar 2026 stood at $44.9 million (down 24.92% YoY), while the FY2025 annual figure was $82.1 million, up 22.63% from the prior year.
- Total Debt for Q1 2026 stood at $44.9 million, down from $82.1 million in the prior quarter.
- The five-year high for Total Debt was $82.1 million in Q4 2025, with the low at $29.8 million in Q2 2022.
- The 5-year median for Total Debt is $59.7 million (2023), against an average of $54.7 million.
- The sharpest annual moves came in 2023 and 2026: Total Debt soared 99.68% in 2023, then retreated 24.92% in 2026.
- Rigel Pharmaceuticals' Total Debt stood at $39.4 million in 2022, then soared by 51.09% to $59.6 million in 2023, then grew by 12.33% to $67.0 million in 2024, then increased by 22.63% to $82.1 million in 2025, then plunged by 45.37% to $44.9 million in 2026.
- Business Quant data shows RIGL's Total Debt at $44.9 million in Q1 2026, $82.1 million in Q4 2025, and $59.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 78.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.47 Mn |
| Mar 31, 2026 | 44.86 Mn |
| Dec 31, 2025 | 82.11 Mn |
| Sep 30, 2025 | 59.73 Mn |
| Jun 30, 2025 | 59.81 Mn |
| Mar 31, 2025 | 59.75 Mn |
| Dec 31, 2024 | 66.95 Mn |
| Sep 30, 2024 | 59.76 Mn |
| Jun 30, 2024 | 59.69 Mn |
| Mar 31, 2024 | 59.69 Mn |
| Dec 31, 2023 | 59.60 Mn |
| Sep 30, 2023 | 59.66 Mn |
| Jun 30, 2023 | 59.57 Mn |
| Mar 31, 2023 | 59.48 Mn |
| Dec 31, 2022 | 39.45 Mn |
| Sep 30, 2022 | 39.47 Mn |
| Jun 30, 2022 | 29.84 Mn |
| Mar 31, 2022 | 29.85 Mn |
| Dec 31, 2021 | 19.91 Mn |
| Sep 30, 2021 | 19.89 Mn |